BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’Donnell DH, Ryan R, Hayes B, Fennelly D, Gibney RG. Hepatocellular carcinoma complicating cystic fibrosis related liver disease. J Cyst Fibros. 2009;8:288-290. [PMID: 19473889 DOI: 10.1016/j.jcf.2009.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2011;1815:214-23. [DOI: 10.1016/j.bbcan.2010.11.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 45] [Article Influence: 1.3] [Reference Citation Analysis]
2 Lavelle LP, Mcevoy SH, Ni Mhurchu E, Gibney RG, Mcmahon CJ, Heffernan EJ, Malone DE. Cystic Fibrosis below the Diaphragm: Abdominal Findings in Adult Patients. RadioGraphics 2015;35:680-95. [DOI: 10.1148/rg.2015140110] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
3 Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol 2017;2017:5128760. [PMID: 28250993 DOI: 10.1155/2017/5128760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
4 Hoskins B, Wasuwanich P, Scheimann AO, Karnsakul W. Screening strategy for gastrointestinal and hepatopancreatobiliary cancers in cystic fibrosis. World J Gastrointest Oncol 2021; 13(9): 1121-1131 [PMID: 34616517 DOI: 10.4251/wjgo.v13.i9.1121] [Reference Citation Analysis]
5 O'Brien C, Ramlaul N, Haughey A, Nolan N, Malone DE, McCormick PA. Hepatocellular carcinoma in cystic fibrosis liver disease: a cautionary tale.QJM. 2019;112:693-694. [PMID: 31214693 DOI: 10.1093/qjmed/hcz150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Haack A, Aragão GG, Novaes MRCG. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J Gastroenterol 2013; 19(46): 8552-8561 [PMID: 24379572 DOI: 10.3748/wjg.v19.i46.8552] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
7 Pals F, Verkade H, Gulmans V, De Koning B, Koot B, De Meij T, Hendriks D, Gierenz N, Vreugdenhil A, Houwen R, Bodewes F. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands. Journal of Cystic Fibrosis 2019;18:385-9. [DOI: 10.1016/j.jcf.2018.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
8 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
9 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
10 Hercun J, Alvarez F, Vincent C, Bilodeau M. Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care. CanLivJ 2019;2:71-83. [DOI: 10.3138/canlivj-2018-0019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]